Therapy Areas: Inflammatory Diseases
Sol-Gel Technologies sells US rights to EPSOLAY and TWYNEO to Mayne Pharma for USD16m
17 April 2025 - Dermatology company Sol-Gel Technologies Ltd (NASDAQ:SLGL) revealed on Thursday that it has entered into a product purchase agreement with a subsidiary of Mayne Pharma Group Limited (A...
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025
16 April 2025 -

Biopharmaceutical company TNF Pharmaceuticals Inc (Nasdaq: TNFA) announced on Wednesday that it presented its oral TNF-alpha inhibit...

Hoth Therapeutics reports positive initial data from Phase 2a pruritus trial
16 April 2025 - US-based biopharmaceutical company Hoth Therapeutics Inc (NASDAQ: HOTH) on Tuesday reported positive interim data from the open-label portion of its Phase 2a clinical trial, CLEER-001,...
Galmed reveals novel pharmacodynamic blood markers for Aramchol SCD1 inhibitor
16 April 2025 - Galmed Pharmaceuticals Ltd (Nasdaq: GLMD), an Israeli clinical-stage biopharmaceutical company focused on developing novel treatments for liver, cardiometabolic and gastrointestinal on...
Evommune initiates EVO756 Phase 2b trial in adults with chronic spontaneous urticaria
16 April 2025 - Clinical stage biotechnology company Evommune Inc announced on Tuesday the enrolment of the first patient in a global Phase 2b trial of EVO756, an orally available, highly potent and s...
Sanofi advances respiratory pipeline with positive amlitelimab data and expanded clinical programmes
15 April 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) on Tuesday reported new clinical data and announced expanded development plans across its respiratory pipeline, ...